Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics

Mindset Pharma: Leaders in Next-Gen Psychedelics

We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF).  We discussed some very exciting news – the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials.  James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement.  He also shared Mindset Pharma’s edge – the buildout of a diverse library of intellectual property.

0:00 Fast tracking MSP-1014 to Phase II Clinical Trials
2:47 Mindset Pharma’s Edge
4:35 Diverse Portfolio of Drugs
6:31 Patents for Non-Hallucinogenic, Non-Tryptamine Compounds
9:06 The Controversy with Psychedelics without the High
11:12 The Rapid Pace of Psychedelics Advancement

Mindset Pharma is a market awareness client of Capital 10X.

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

LEAVE A REPLY

Please enter your comment!
Please enter your name here